PHARMA INFLUENCERS | NEWSLETTERS | WEBINARS

Thursday, December 5, 2019

RESEARCH AND DEVELOPMENT


Newsletter

RESEARCH AND DEVELOPMENT from The Pharmaceutical Marketing Group is a regular email newsletter with news from the pharmaceutical industry

Direct to your inbox

Stay up to date with the latest appointments by subscribing to RESEARCH AND DEVELOPMENT! from The Pharmaceutical Marketing Group

View the newsletter archive

Research and Development

Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

Lucy Muniz -
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH /...
Read more
Research and Development

Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder

Lucy Muniz -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company...
Read more
Research and Development

Meissa Vaccines Receives FDA Clearance of IND Application for a Phase 1 Clinical Trial of MV-012-968 for Respiratory Syncytial Virus

Lucy Muniz -
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Meissa Vaccines (“Meissa”), a biotechnology...
Read more
Research and Development

NeuClone Announces Positive Results from Phase I Study of Herceptin® (Trastuzumab) Biosimilar Candidate

Lucy Muniz -
SYDNEY--(BUSINESS WIRE)--NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company...
Read more
Research and Development

Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM

Lucy Muniz -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the...
Read more
Research and Development

AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

Lucy Muniz -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that...
Read more
Research and Development

Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease

Lucy Muniz -
BOSTON--(BUSINESS WIRE)--Cerevance, a clinical stage biopharmaceutical company advancing new...
Read more
Research and Development

Aldeyra Therapeutics to Host Conference Call and Webcast to Announce Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye...

Lucy Muniz -
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will...
Read more
Research and Development

NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers

Lucy Muniz -
CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage...
Read more
Research and Development

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial...

Lucy Muniz -
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and...
Read more
Research and Development

PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

Lucy Muniz -
SAN FRANCISCO--(BUSINESS WIRE)--PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq:...
Read more
Research and Development

Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis

Lucy Muniz -
BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
Read more

© Copyright - The Pharmaceutical Marketing Group